Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Operating Income (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Operating Income for 12 consecutive years, with -$15.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Income fell 483.53% year-over-year to -$15.8 million, compared with a TTM value of $23.2 million through Sep 2025, up 246.45%, and an annual FY2024 reading of $25.0 million, up 485.49% over the prior year.
  • Operating Income was -$15.8 million for Q3 2025 at CytomX Therapeutics, down from -$1.3 million in the prior quarter.
  • Across five years, Operating Income topped out at $22.6 million in Q1 2025 and bottomed at -$32.1 million in Q1 2022.
  • Average Operating Income over 5 years is -$7.2 million, with a median of -$5.7 million recorded in 2023.
  • The sharpest move saw Operating Income plummeted 737.84% in 2021, then soared 3017.33% in 2024.
  • Year by year, Operating Income stood at -$2.6 million in 2021, then plummeted by 259.78% to -$9.5 million in 2022, then soared by 93.63% to -$606000.0 in 2023, then skyrocketed by 3017.33% to $17.7 million in 2024, then plummeted by 189.18% to -$15.8 million in 2025.
  • Business Quant data shows Operating Income for CTMX at -$15.8 million in Q3 2025, -$1.3 million in Q2 2025, and $22.6 million in Q1 2025.